ARTICLE | Company News
Leo Pharma, Virobay deal
January 16, 2012 8:00 AM UTC
Virobay granted LEO exclusive, worldwide rights to develop an undisclosed oral cathepsin inhibitor. The product is in preclinical testing to treat psoriasis, with Phase I testing expected to start in ...